Liver manifestation associated with covid-19 (Literature review)

he World Health Organization (WHO) named the 2019-nCoV virus on January 12, 2020 [1]. Subsequently, in a short period of time, Novel Coronavirus Infected Pneumonia (NCIP) spread around the world, and on January 30, 2020, the WHO declared NCIP an international public health emergency [2]. On February 11, 2020, it was renamed Coronavirus Disease 2019 (COVID-19) [3]. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which has been described as a form of the beta coronavirus cluster, is the cause of the pandemic and has 79.6% sequence identity with SARS-CoV [4]. COVID-19 is generally a self-limiting disease, but it can also be fa-tal: China’s death rate is around 2.3 percent [5], from 5.8 percent in Wuhan to 0.7 percent in the rest of China [6]. The proportion of serious or fatal infections that can be attributed to specific infected populations may vary by country and region. A certain percentage of deaths oc-curred in elderly patients or comorbid conditions (obesity, hypertension, diabetes, cardiovascular disease, chronic lung disease and cancer) [5;7;8]. These results were also found in critically ill patients re-ferred to the intensive care unit, indicating that adequate liver oxygen supply is provided by compensatory mecha-nisms, including in cases of severe respiratory failure during COVID-19 disease [9;10;11;12-17]. © 2021, Venezuelan Society of Pharmacology and Clinical and Therapeutic Pharmacology. All rights reserved.